News & Updates
Filter by Specialty:
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024Folic acid may induce toxicities in capecitabine-treated CRC patients
The presence of folic acid in plasma and intake of folic acid supplements appear to contribute to chemotherapy-induced toxicities in patients treated with capecitabine for colorectal cancer (CRC), reports a recent study.
Folic acid may induce toxicities in capecitabine-treated CRC patients
09 Feb 2024Do dairy products increase breast cancer risk?
Women who regularly consume dairy products do not have an increased risk of developing breast cancer, reveals a study. However, there is heterogeneity seen for the type of dairy food, period of life, and tumour subtypes.
Do dairy products increase breast cancer risk?
08 Feb 2024Does radiotherapy improve survival in NSCLC patients with cachexia?
Palliative-intent radiation was performed more frequently in patients with advanced nonsmall-cell lung cancer (NSCLC) and cachexia than those without weight loss. Unfortunately, tumour-directed therapy, whether in a curative or a palliative approach, proves inadequate in improving cachexia patient survival across all stages of the disease.